clinical trial · NCT05806138
A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
Breast CancerCardiac DysfunctionVericiguatOptimal medical therapy
brief summary
The purpose of this study is to find out if adding vericiguat to standard treatment for cancer therapy related cardiac dysfunction (CTRCD) is more effective than standard treatment alone. The addition of vericiguat to the usual treatment could help improve cardiac function, but it could also cause side effects. This study will help researchers find out whether this different treatment is better, the same as, or worse than the usual approach.
started
Jul 17, 2023
primary completion
Jul 17, 2028
completion
Jul 17, 2028
last updated
Jul 31, 2025
official title
A Randomized Controlled Trial of the Soluble Guanylate Cyclase Stimulator Vericiguat in Patients With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction (ELEVATE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol